US2008069859A1PendingUtilityA1

Method for treating neovascularization and intravitreal implants

Assignee: ALLERGAN INCPriority: Nov 29, 2000Filed: Nov 21, 2007Published: Mar 20, 2008

Est. expiryNov 29, 2020(expired)· nominal 20-yr term from priority

A61P 37/06A61P 41/00A61P 9/00A61P 43/00A61P 27/00A61P 27/02A61L 2300/604A61K 31/765A61L 2300/222A61L 2300/416A61K 9/0051A61K 47/34A61K 31/56A61L 2300/41A61K 31/573A61L 27/54A61K 9/1647A61K 45/06A61F 9/0017A61K 31/715A61K 9/1641A61F 9/0008A61F 2210/0004A61K 9/0048

PatentIndex Score

Cited by

References

Claims

Abstract

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Claims

exact text as granted — not AI-modified

1 . (canceled)  
     
     
         2 . A method for treating neovascularization in an eye of an individual, the method comprising implanting in the vitreous of an eye prone to neovascularization an intravitreal, biodegradable drug delivery system comprising an immunosuppressive agent and a polylactic acid polyglycolic acid (PLGA) copolymer.  
     
     
         3 . The method of  claim 2 , wherein said immunosuppressive agent is a steroid.  
     
     
         4 . The method of  claim 3  wherein the steroid is dexamethasone.  
     
     
         5 . The method of  claim 3 , wherein the steroid comprises about 10% to 90% of the weight of the intravitreal, bioerodible drug delivery system.  
     
     
         6 . The method of  claim 5 , wherein the steroid comprises about 50% to about 80% by weight of the drug delivery system.

Join the waitlist — get patent alerts

Track US2008069859A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.